Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
29.69
+2.31 (8.44%)
May 27, 2026, 4:00 PM EDT - Market closed
Sutro Biopharma Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Sutro Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $46.55. The average 1-year stock price forecast is 56.79% higher than the current stock price, while the lowest is $9.00 (-69.69%) and the highest is $61 (+105.46%).
Price Target: $46.55 (+56.79%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Sutro Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 6 | 8 | 9 |
| Buy | 1 | 2 | 2 | 2 | 2 | 1 |
| Hold | 4 | 3 | 3 | 1 | 1 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Sell Reiterates n/a | Sell | Reiterates | n/a | n/a | May 22, 2026 |
| Wedbush | Wedbush | Buy Upgrades $60 | Buy | Upgrades | $60 | +102.09% | May 18, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $54 | Buy | Maintains | $54 | +81.88% | May 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $28 → $50 | Buy | Reiterates | $28 → $50 | +68.41% | May 15, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $38 → $43 | Buy | Reiterates | $38 → $43 | +44.83% | May 15, 2026 |
Financial Forecast
Revenue This Year
39.84M
from 102.48M
Decreased by -61.13%
Revenue Next Year
28.09M
from 39.84M
Decreased by -29.48%
EPS This Year
-9.65
from -22.49
EPS Next Year
-7.65
from -9.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 63.0M | 63.0M | ||||||
| Avg | 39.8M | 28.1M | ||||||
| Low | 9.8M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -38.5% | 58.2% | ||||||
| Avg | -61.1% | -29.5% | ||||||
| Low | -90.4% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -5.29 | -5.10 | ||||||
| Avg | -9.65 | -7.65 | ||||||
| Low | -15.43 | -10.44 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.